BeiGene

Slide kit outlining a new therapeutic approach for previously untreated chronic lymphocytic leukemia (CLL)

Jake Shortt

Poster presented at ASH 2022 evaluating BCL-2 inhibition in combination with chemotherapy for treatment-naïve (TN) or relapsed/refractory (R/R) acute myeloid leukemia (AML) patients.

Chatta med BeiGene

Stäng